-
-
-
Fosun Pharma’s Independently Developed Innovative Drug XH-S003 Capsule for PNH Indication Approved for Clinical Trials
2025-03-13
March 13, 2025 – Fosun Pharma announced that its subsidiary S-INFINITY Co., Ltd. (“S-INFINITY”) recently received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for XH-S003 Capsule (registration category: chemical drug Class 1; hereinafter referred to as “XH-S003”) for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). S-INFINITY plans to initiate Phase 2 clinical trials in Mainland China (excluding Hong Kong, Macao, and Taiwan regions) once conditions are met.
-
-
-
-
Fosun Pharma's Independently Developed Innovative Lung Cancer Drug Foritinib (SAF-189) Marketing Authorization Application Has Been Accepted by NMPA
2025-03-10
March 10, 2025 – Recently, Fosun Pharma announced that the marketing authorization application for its independently developed new drug, foritinib Succinate Capsules (project code: SAF-189, foritinib, hereinafter referred to as "New Drug"), has been accepted by the National Medical Products Administration (NMPA). The New Drug is primarily indicated for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+), etc. The indication under this application is for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
-
-
-
-
Henlius Successfully Holds First In-Person Investigator Meeting in Japan, Accelerating Global Clinical Research for Innovative Pipeline
2025-03-05
Recently, Henlius successfully hosted an in-person clinical investigator meeting for the HLX22-GC-301 study in Tokyo, Japan. The meeting focused on the international phase 3 clinical trial (HLX22-GC-301) of HLX22, our innovative anti-HER2 monoclonal antibody (mAb)
-
-
-
-
Updated Long-term Survival Results from the International Multicenter Phase 3 Clinical Trial of HANQUYOU Published in The Breast
2025-02-26
Recently, the updated 3-year follow-up results of the international multicenter Phase 3 clinical trial HLX02-BC01(NCT03084237 and EudraCT: 2016-000206-10) of HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), led by Academician Binghe Xu, director of the National New Drug (Antitumor) Clinical Research Center of Cancer Hospital Chinese Academy of Medical Sciences, were published in the professional breast cancer journal The Breast. The follow-up analysis results demonstrated that HANQUYOU exhibited comparable long-term efficacy, safety, and immunogenicity to the reference trastuzumab in patients with previously untreated HER2-positive metastatic breast cancer, further validating their clinical equivalence.
-
-
-
-
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
2025-02-26
(26 February, 2025, Shanghai, China) — Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. (“Fosun Pharma Industrial”), has received approval from the National Medical Products Administration (“NMPA”) for the New Drug Application (“NDA”) for Tenapanor Hydrochloride Tablets (Chinese trade name: Wan Ti Le, the “New Drug”), an innovative phosphate absorption inhibitor with a novel mechanism, with the indication being for the control of serum phosphorus levels in dialysis patients with chronic kidney disease (CKD) who have an inadequate response or are intolerant to phosphorus binders.
-
-
-
-
Fosun Tourism Group Officially Establishes AI Lab, Leading the New Era of AI-Powered Vacations
2025-02-25
Recently, Fosun Tourism Group announced the establishment of AI Lab, focusing on the application, innovation, and implementation of artificial intelligence technology in the tourism and vacation sector. AI Lab is currently working on the development of AI G.O (AI Gentle Organizer), which will use advanced models such as DeepSeek, combined with multimodal interaction and machine learning algorithms, to provide personalized services throughout the customer journey, reconstructing every experience at Fosun Tourism Group’s destinations and resorts.
-
-
-
-
Guo Guangchang: Fosun Emphasizes Strategic Advancement and Exits, Focuses on Core Businesses, and Leverages Operational Capabilities to Participate in Global Markets
2025-02-22
On 21 February, Guo Guangchang, Chairman of Fosun International spoke at the 25th Annual Conference of Yabuli China Entrepreneurs Forum 2025, stating that private enterprises are not afraid of competition as long as there are fair opportunities for participation. A strong commitment to product excellence will certainly lead to market opportunities.
-
-
-
-
Fosun Health Cloud HIS Launches DeepSeek AI Assistant, Ushering in a New Era of Medical Services
2025-02-21
In the wave of technological innovation, artificial intelligence (AI) has become a pivotal force driving transformation in the healthcare industry. Fosun Health, a leading medical and health technology group in China, has deeply integrated cutting-edge large model technologies and has taken the lead in adopting DeepSeek-R1, continuously exploring new frontiers in smart healthcare.
-
-
-
-
Fosun Joins Hands with Abu Dhabi Investment Office, Adding New Momentum to Middle East Strategy
2025-02-20
Fosun’s global operations achieved another milestone. On February 20, during the Abu Dhabi Investment Forum in Shanghai, Fosun International signed a Memorandum of Strategic Cooperation with the Abu Dhabi Investment Office (ADIO). This collaboration aims to drive the expansion of Fosun’s subsidiaries into Abu Dhabi and the broader Middle East region, injecting fresh momentum into Fosun’s global presence and industrial operations.
-